Healthcare · Biotechnology

Amgen Inc.

NASDAQAMGN ISINUS0311621009 SEC CIK0000318154 Listed on NASDAQ · USD

$471.01 +2.89 (+0.62%) Pre-market $472.06 (+0.84%) ≈ ₹44,205 a share

Open chart

Price, last 12 months+46.19% in a year

Key numbers

Market value: $254.77B
P/E (TTM): 27.3
Forward P/E: 19.9
EPS (TTM): $17.25
Dividend yield: 2.14%
Beta: 0.42
Day range: $467.17 – $474.00
52-week range: $312.39 – $483.99
Volume: 233,728
10-day avg volume: $2.96M
Revenue (TTM): $38.90B
EBITDA (TTM): $17.70B
Gross margin: 72.5%
Net margin: 24.1%
Return on equity: 78.4%
Debt / equity: 376.3%
Price / sales: 6.55
Shares out: 540.91M

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$8.20B$1.27B$767.00M

Dec 23

$7.45B$991.00M$-113.00M

Mar 24

$8.39B$1.91B$746.00M

Jun 24

$8.50B$2.05B$2.83B

Sep 24

$9.09B$2.31B$627.00M

Dec 24

$8.15B$1.18B$1.73B

Mar 25

$9.18B$2.66B$1.43B

Jun 25

$9.56B$2.53B$3.22B

Sep 25

$9.87B$2.72B$1.33B

Dec 25

$8.62B$2.67B$1.82B

Mar 26

$10.05B$3.51B$2.38B

Jun 26

$10.37B$3.71B$3.86B

Sep 26

Revenue · QoQ (vs last quarter)

—-9.1%+13%+1.4%+6.9%-10%+13%+4.1%+3.2%-13%+17%+3.1%

Revenue · YoY (vs a year ago)

————+11%+9.4%+9.4%+12%+8.6%+5.8%+9.5%+8.5%

Net income · QoQ (vs last quarter)

—-115%+760%+279%-78%+176%-17%+125%-59%+36%+31%+63%

Net income · YoY (vs a year ago)

————-18%+1,631%+92%+14%+113%+5.1%+66%+20%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$8.20B	$7.45B	$8.39B	$8.50B	$9.09B	$8.15B	$9.18B	$9.56B	$9.87B	$8.62B	$10.05B	$10.37B
Cost of revenue	$3.11B	$3.20B	$3.24B	$3.31B	$3.11B	$2.97B	$3.01B	$3.08B	$2.98B	$2.74B	$2.81B	$2.79B
Gross profit	$5.08B	$4.25B	$5.15B	$5.19B	$5.97B	$5.18B	$6.17B	$6.48B	$6.89B	$5.87B	$7.24B	$7.58B
Gross margin	62.0%	57.0%	61.4%	61.1%	65.7%	63.6%	67.2%	67.8%	69.8%	68.2%	72.0%	73.1%
Selling, general & admin	$2.27B	$1.81B	$1.79B	$1.63B	$1.88B	$1.69B	$1.69B	$1.72B	$1.95B	$1.60B	$1.75B	$1.68B
Operating income	$1.27B	$991.00M	$1.91B	$2.05B	$2.31B	$1.18B	$2.66B	$2.53B	$2.72B	$2.67B	$3.51B	$3.71B
Operating margin	15.5%	13.3%	22.8%	24.1%	25.4%	14.5%	28.9%	26.4%	27.6%	30.9%	35.0%	35.8%
Pre-tax income	$852.00M	$-68.00M	$794.00M	$3.10B	$782.00M	$1.97B	$1.57B	$3.92B	$1.51B	$2.08B	$2.77B	$4.69B
Income tax	$85.00M	$45.00M	$48.00M	$271.00M	$155.00M	$243.00M	$136.00M	$705.00M	$181.00M	$265.00M	$393.00M	$822.00M
Net income	$767.00M	$-113.00M	$746.00M	$2.83B	$627.00M	$1.73B	$1.43B	$3.22B	$1.33B	$1.82B	$2.38B	$3.86B
Net margin	9.4%	-1.5%	8.9%	33.3%	6.9%	21.2%	15.6%	33.7%	13.5%	21.1%	23.6%	37.3%
EPS (diluted)	—	$-0.21	$1.38	$5.22	—	$3.20	$2.65	$5.93	—	$3.34	$4.37	$7.08

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$23.75B$19.65B$8.39B

FY18

$23.36B$19.01B$7.84B

FY19

$25.42B$19.27B$7.26B

FY20

$25.98B$19.53B$5.89B

FY21

$26.32B$19.92B$6.55B

FY22

$28.19B$19.74B$6.72B

FY23

$33.42B$20.57B$4.09B

FY24

$36.75B$24.71B$7.71B

FY25

Revenue · YoY (vs a year ago)

—-1.6%+8.8%+2.2%+1.3%+7.1%+19%+10.0%

Net income · YoY (vs a year ago)

—-6.6%-7.4%-19%+11%+2.5%-39%+89%

RevenueGross profitNet incomeLine = trend

$12.62

FY18

$12.88

FY19

$12.31

FY20

$10.28

FY21

$12.11

FY22

$12.49

FY23

$7.56

FY24

$14.23

FY25

EPS (diluted) · YoY (vs a year ago)

—+2.1%-4.4%-16%+18%+3.1%-39%+88%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$23.75B	$23.36B	$25.42B	$25.98B	$26.32B	$28.19B	$33.42B	$36.75B
Revenue growth	—	-1.6%	8.8%	2.2%	1.3%	7.1%	18.6%	10.0%
Cost of revenue	$4.10B	$4.36B	$6.16B	$6.45B	$6.41B	$8.45B	$12.86B	$12.04B
Gross profit	$19.65B	$19.01B	$19.27B	$19.53B	$19.92B	$19.74B	$20.57B	$24.71B
Gross margin	82.7%	81.4%	75.8%	75.2%	75.7%	70.0%	61.5%	67.2%
Selling, general & admin	$5.33B	$5.15B	$5.73B	$5.37B	$5.41B	$6.18B	$7.10B	$7.05B
Operating income	$10.26B	$9.67B	$9.14B	$7.64B	$9.57B	$7.90B	$7.26B	$9.08B
Operating margin	43.2%	41.4%	35.9%	29.4%	36.3%	28.0%	21.7%	24.7%
Depreciation & amortisation	$1.95B	$2.21B	$3.60B	$3.40B	$3.42B	$4.07B	$5.59B	$5.17B
Pre-tax income	$9.55B	$9.14B	$8.13B	$6.70B	$7.35B	$7.86B	$4.61B	$8.98B
Income tax	$1.15B	$1.30B	$869.00M	$808.00M	$794.00M	$1.14B	$519.00M	$1.27B
Tax rate	12.1%	14.2%	10.7%	12.1%	10.8%	14.5%	11.3%	14.1%
Net income	$8.39B	$7.84B	$7.26B	$5.89B	$6.55B	$6.72B	$4.09B	$7.71B
Net margin	35.3%	33.6%	28.6%	22.7%	24.9%	23.8%	12.2%	21.0%
EPS (diluted)	$12.62	$12.88	$12.31	$10.28	$12.11	$12.49	$7.56	$14.23

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$12.50B$33.93B$29.30B

FY18

$9.67B$29.90B$8.91B

FY19

$9.41B$32.99B$10.65B

FY20

$6.70B$33.31B$8.04B

FY21

$3.66B$38.95B$9.31B

FY22

$6.23B$64.61B$10.94B

FY23

$5.88B$60.10B$11.97B

FY24

$8.66B$54.60B$9.13B

FY25

Shareholders' equity · YoY (vs a year ago)

—-23%-2.7%-29%-45%+70%-5.7%+47%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$6.95B	$6.04B	$6.27B	$7.99B	$7.63B	$10.94B	$11.97B	$9.13B
Short-term investments	$22.36B	$2.87B	$4.38B	$48.00M	$1.68B	$0	—	—
Current assets	$37.62B	$18.44B	$21.14B	$19.39B	$22.19B	$30.33B	$29.03B	$29.06B
Total assets	$66.42B	$59.71B	$62.95B	$61.17B	$65.12B	$97.15B	$91.84B	$90.59B
Current liabilities	$13.49B	$12.84B	$11.65B	$12.18B	$15.69B	$18.39B	$23.10B	$25.49B
Long-term debt	$29.51B	$26.95B	$32.90B	$33.22B	$37.35B	$63.17B	$56.55B	$50.01B
Short-term debt	$4.42B	$2.95B	$91.00M	$87.00M	$1.59B	$1.44B	$3.55B	$4.60B
Total debt	$33.93B	$29.90B	$32.99B	$33.31B	$38.95B	$64.61B	$60.10B	$54.60B
Shareholders' equity	$12.50B	$9.67B	$9.41B	$6.70B	$3.66B	$6.23B	$5.88B	$8.66B
Current ratio	2.79	1.44	1.81	1.59	1.41	1.65	1.26	1.14
Debt / equity	2.71	3.09	3.51	4.97	10.64	10.37	10.23	6.31
Return on equity	67.2%	81.1%	77.2%	88.0%	179.0%	107.8%	69.6%	89.1%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$11.30B$10.56B$21.30B

FY18

$9.15B$8.53B$11.21B

FY19

$10.50B$9.89B$7.24B

FY20

$9.26B$8.38B$8.99B

FY21

$9.72B$8.79B$10.56B

FY22

$8.47B$7.36B$4.56B

FY23

$11.49B$10.39B$5.03B

FY24

$9.96B$8.10B$5.12B

FY25

Operating cash flow · YoY (vs a year ago)

—-19%+15%-12%+5.0%-13%+36%-13%

Free cash flow · YoY (vs a year ago)

—-19%+16%-15%+4.8%-16%+41%-22%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$11.30B	$9.15B	$10.50B	$9.26B	$9.72B	$8.47B	$11.49B	$9.96B
Capital spending	$-738.00M	$-618.00M	$-608.00M	$-880.00M	$-936.00M	$-1.11B	$-1.10B	$-1.86B
Free cash flow	$10.56B	$8.53B	$9.89B	$8.38B	$8.79B	$7.36B	$10.39B	$8.10B
FCF margin	44.5%	36.5%	38.9%	32.3%	33.4%	26.1%	31.1%	22.0%
Stock-based pay	$311.00M	$308.00M	$330.00M	$341.00M	$401.00M	$431.00M	$530.00M	$494.00M
Cash from investing	$14.34B	$5.71B	$-5.40B	$733.00M	$-6.04B	$-26.20B	$-1.05B	$-1.94B
Cash from financing	$-22.49B	$-15.77B	$-4.87B	$-8.27B	$-4.04B	$21.05B	$-9.42B	$-10.86B
Dividends paid	$-3.51B	$-3.51B	$-3.76B	$-4.01B	$-4.20B	$-4.56B	$-4.83B	$-5.12B
Share buybacks	$-17.79B	$-7.70B	$-3.49B	$-4.98B	$-6.36B	$0	$-200.00M	$0

About

About Amgen Inc.

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Amgen Inc.
Ticker: AMGN
Exchange: NASDAQ
ISIN: US0311621009
SEC CIK: 0000318154
Sector: Healthcare
Industry: Biotechnology
SEC industry (SIC): Biological Products, (no Diagnostic Substances) (2836)
Incorporated in: Delaware
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 13 Feb 2026
CEO: Robert A. Bradway
Chair: Robert A. Bradway
Headquarters: Thousand Oaks, California, United States
Address: One Amgen Center Drive, Thousand Oaks, Ca 91320
Founded: 1980
Employees: 31,500
Trades in: US dollars (USD)
Website: amgen.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Amgen Inc.

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers